Yu Chen Barrett

4.0k total citations · 1 hit paper
25 papers, 2.9k citations indexed

About

Yu Chen Barrett is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Hematology. According to data from OpenAlex, Yu Chen Barrett has authored 25 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Cardiology and Cardiovascular Medicine, 8 papers in Internal Medicine and 6 papers in Hematology. Recurrent topics in Yu Chen Barrett's work include Atrial Fibrillation Management and Outcomes (13 papers), Venous Thromboembolism Diagnosis and Management (8 papers) and Biosimilars and Bioanalytical Methods (5 papers). Yu Chen Barrett is often cited by papers focused on Atrial Fibrillation Management and Outcomes (13 papers), Venous Thromboembolism Diagnosis and Management (8 papers) and Biosimilars and Bioanalytical Methods (5 papers). Yu Chen Barrett collaborates with scholars based in United States, Sweden and Germany. Yu Chen Barrett's co-authors include Charles Frost, Frank LaCreta, Andrew Shenker, Viswanath Devanarayan, Zhaoqing Wang, Jessie Wang, Alan Schuster, Rebecca A. Boyd, Gopi Shankar and Linda A. Zuckerman and has published in prestigious journals such as Blood, European Heart Journal and Pharmaceutical Research.

In The Last Decade

Yu Chen Barrett

25 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement

2006 504 citations Jean W. Lee, Viswanath Devanarayan et al. Pharmaceutical Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yu Chen Barrett United States	17	1.3k	894	847	696	670	25	2.9k
Uma Sinha United States	29	1.2k 0.9×	337 0.4×	812 1.0×	746 1.1×	134 0.2×	109	2.9k
Richard D. Hockett United States	25	2.0k 1.6×	1.1k 1.3×	482 0.6×	927 1.3×	139 0.2×	47	4.9k
Ahmed Hasan United States	20	686 0.5×	553 0.6×	114 0.1×	475 0.7×	75 0.1×	46	2.5k
Benjamin Lang United States	21	535 0.4×	270 0.3×	376 0.4×	503 0.7×	50 0.1×	62	1.5k
Alexander Staab Germany	23	376 0.3×	174 0.2×	182 0.2×	445 0.6×	146 0.2×	54	2.0k
Vijay Upreti United States	20	276 0.2×	171 0.2×	166 0.2×	403 0.6×	128 0.2×	55	1.7k
Benoı̂t Blanchet France	36	327 0.3×	220 0.2×	106 0.1×	965 1.4×	180 0.3×	139	3.6k
Manisha Bhutani United States	27	213 0.2×	185 0.2×	223 0.3×	1.0k 1.5×	227 0.3×	144	2.8k
Francesco Dati Germany	22	881 0.7×	167 0.2×	97 0.1×	216 0.3×	373 0.6×	77	2.3k
David Trent United States	19	408 0.3×	102 0.1×	630 0.7×	872 1.3×	117 0.2×	27	3.8k

Countries citing papers authored by Yu Chen Barrett

Since Specialization

Citations

This map shows the geographic impact of Yu Chen Barrett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Chen Barrett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Chen Barrett more than expected).

Fields of papers citing papers by Yu Chen Barrett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Chen Barrett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Chen Barrett. The network helps show where Yu Chen Barrett may publish in the future.

Co-authorship network of co-authors of Yu Chen Barrett

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Chen Barrett. A scholar is included among the top collaborators of Yu Chen Barrett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Chen Barrett. Yu Chen Barrett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Olivotto, Iacopo, Pablo García‐Pavía, Zhuang Tian, et al.. (2025). Integrated efficacy and safety analysis of mavacamten monotherapy in patients with obstructive hypertrophic cardiomyopathy. European Heart Journal. 46(Supplement_1). 1 indexed citations

Li, Xiaoyan, Qing Zhang, Jianan Wang, et al.. (2025). Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study. Cardiology and Therapy. 14(2). 267–282. 1 indexed citations

Sullivan, Patrick W., Vahram Ghushchyan, Jessica Marvel, Yu Chen Barrett, & Anne L. Fuhlbrigge. (2019). Association Between Pulmonary Function and Asthma Symptoms. The Journal of Allergy and Clinical Immunology In Practice. 7(7). 2319–2325. 27 indexed citations

Yetman, Robert J., Yu Chen Barrett, Zhaoqing Wang, et al.. (2017). Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma. Thrombosis and Haemostasis. 117(8). 1518–1527. 9 indexed citations

Frost, Charles, Yan Song, Andrew Shenker, et al.. (2015). Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban. Clinical Pharmacokinetics. 54(6). 651–662. 75 indexed citations

Frost, Charles, Yan Song, Yu Chen Barrett, et al.. (2014). A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clinical Pharmacology Advances and Applications. 6. 179–179. 97 indexed citations

Frost, Charles, Andrew Shenker, Janice Pursley, et al.. (2014). Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. British Journal of Clinical Pharmacology. 78(4). 877–885. 49 indexed citations

Frost, Charles, Sunil Nepal, Jessie Wang, et al.. (2013). Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factorXa inhibitor, in healthy subjects. British Journal of Clinical Pharmacology. 76(5). 776–786. 225 indexed citations

Frost, Charles, Cui Yi-min, Yan Song, et al.. (2013). Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clinical Pharmacology Advances and Applications. 5. 177–177. 32 indexed citations

10.

Upreti, Vijay, Jessie Wang, Yu Chen Barrett, et al.. (2013). Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. British Journal of Clinical Pharmacology. 76(6). 908–916. 209 indexed citations

11.

Wang, Jessie J., Yan Song, Janice Pursley, et al.. (2012). A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thrombosis and Haemostasis. 107(5). 916–924. 49 indexed citations

12.

Wang, Zhaoqing, Charles Frost, Andrew Shenker, & Yu Chen Barrett. (2010). Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay. Thrombosis and Haemostasis. 104(12). 1263–1271. 296 indexed citations

13.

Wang, Jessie J., Robert M. Knabb, Puneet Mohan, & Yu Chen Barrett. (2010). Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis. 105(1). 181–189. 21 indexed citations

14.

Barrett, Yu Chen, Jessie Wang, Zhigang Yu, et al.. (2008). Apixaban Treatment Decreases Coagulation Activity in Patients with Acute Deep-Vein Thrombosis.. Blood. 112(11). 1982–1982. 4 indexed citations

15.

Shankar, Gopi, Viswanath Devanarayan, Lakshmi Amaravadi, et al.. (2008). Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. Journal of Pharmaceutical and Biomedical Analysis. 48(5). 1267–1281. 444 indexed citations

16.

Barrett, Yu Chen, William F. Ebling, Henry J. Pieniaszek, Jeffrey T. Billheimer, & Dietmar Seiffert. (2007). Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonist. Journal of Pharmaceutical and Biomedical Analysis. 44(4). 938–946. 10 indexed citations

17.

Lee, Jean W., Viswanath Devanarayan, Yu Chen Barrett, et al.. (2006). Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement. Pharmaceutical Research. 23(2). 312–328. 504 indexed citations breakdown →

18.

Mire‐Sluis, Anthony R., Yu Chen Barrett, Viswanath Devanarayan, et al.. (2004). Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. Journal of Immunological Methods. 289(1-2). 1–16. 463 indexed citations

19.

Pieniaszek, Henry J., Harry L. Walton, Donald Pinto, et al.. (2002). A double antibody radioimmunoassay for the determination of XV459, the active hydrolysis metabolite of roxifiban, in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 30(5). 1441–1449. 7 indexed citations

20.

Barrett, Yu Chen. (1994). Characterization of radical formation and iron oxidation/hydrolysis during iron deposition in ferritin. University of New Hampshire Scholars Repository (University of New Hampshire at Manchester). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact